We all reach moments of reflection. An incident or series of events that makes you take a breath, step back and evaluate what has gone by and what might be to come. As a nation, we’ve had too many of these moments in the last few months.
At this point in 2019 it is impossible not to give some well-deserved attention to the departure of Dr. Scott Gottlieb from the U.S. Food and Drug Administration (FDA). Anyone associated with pharmaceuticals or packaging was surprised at the announcement.
The pharmaceutical industry’s understanding of serialization is maturing as companies slowly begin to recognize the added business value supply chain traceability can provide. Historically, the industry’s focus on serialization has been driven by the need to satisfy evolving regulations. However, companies are realizing that the benefits of traceability extend beyond compliance.
Up and down the supply chain, the pharmaceutical industry will work hard to achieve traceability per DSCSA standards. Greater consumer demand and a heightened focus of customization at the patient level will force smaller batches and shorter lead times for packagers. Through all of the changes, quality management remains top-of-mind for pharmaceutical packaging manufacturers.
